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DOI 10.1016/j.stem.2009.09.008Mouse and human fibroblasts were the
first cell types successfully reprog-
rammed by ectopic expression of OCT4,
SOX2, KLF4, and c-MYC (OSKM) (Lowry
et al., 2008; Maherali et al., 2007; Park
et al., 2008; Takahashi et al., 2007; Taka-
hashi and Yamanaka, 2006; Yu et al.,
2007). Further studies have shown that
the age, origin, and cell type used have
a deep impact on the reprogramming effi-
ciency, eventually requiring the expres-
sion of fewer factors and/or reducing the
timing of the whole process. In general,
stem cells are rare and difficult to access
and isolate in large numbers (neural stem
cells, for instance [Kim et al., 2008,
2009c]) and, therefore, represent a com-
plicated target for reprogramming. How-
ever, Cord Blood (CB) could represent an
alternative and readily accessible source
of stem cells. Here, we describe reprog-
ramming of CB cells to pluripotency by
retroviral transduction of four (OSKM),
three (OSK), and as few as two (OS) tran-
scription factors, without the need for
additional chemical compounds.
CB cells are considered an alternative to
bone marrow (BM) as a source of hemato-
poietic stem cells for transplantation. CB
cells can be collected without any risk for
the donor, are young cells expected to
carry minimal somatic mutations, and
possess the immunological immaturity of
newborn cells (Rocha et al., 2004). These
properties allow for less stringent criteria
for HLA-donor-recipient selection, which
represents a decisive benefit for trans-
plantation and has resulted in more than
400,000 immunologically characterized
CB units being currently available world-
wide through a network of CB banks
(Gluckman and Rocha, 2009).For these experiments, CB-derived
stem cells were isolated using standard
CD133 immunomagnetic selection, ob-
taining a purity range of 90%–94% (Figure
S1A available online). Because the integra-
tion and expression of retroviral constructs
requires mitotic division of the target cells,
we first culture the quiescent CB cells for
24 hr in the presence of stem cell factor
(SCF), Trombopoietin (TPO), Flt ligand 3
(FLT-3), and Interleukin 6 (IL-6) (Akkina
et al., 1996). Then, the cells were seeded
over retronectin-coated plates previously
preadsorbed with the viral particles, as
previously described (Gammaitoni et al.,
2006). Using this approach, we obtained
an infection efficiency of approximately
28%, as monitored by a constitutive GFP
reporter retrovirus. Within the GFP+ popu-
lation, 61% were CD133+, while 39%
were CD133 (Figure S1B).
We first asked if maintaining CB cells
under hESC culture conditions could be
sufficient to induce reprogramming, as it
has recently been shown to be the case
for spermatogonial stem cells (Conrad
et al., 2008). After 3 weeks of culture un-
der these conditions, CB cells formed no
colonies. Flow cytometry analysis re-
vealed that the resulting cells no longer
expressed the hematopoietic stem cells
markers CD133, CD34, and CD38 and re-
mained positive for the hematopoietic
marker CD45, but did not acquire the
embryonic markers SSEA-3, SSEA-4, or
TRA1-60, suggesting that untransduced
CB cells differentiate into mature hemato-
poietic cells when cultured in hESC condi-
tions (Figure S1C).
We then attempted to reprogram CB
cells using OSKM, OSK (either a combina-
tion of single factors or a polycistronicCell Stem Celconstructs, see Figures S2A and S2B),
and OS. Three days posttransduction,
cells were plated onto irradiated Human
Foreskin Fibroblasts (HFF-1) feeder cells
and cultured in hES medium. As early
as 9 days postinfection, small colonies
started to appear in cells transduced with
OSKM, OSK, and OS. At 12–15 days post-
infection, some of the colonies exhibited
typical hESC morphology with sharp
borders and were comprised of a small,
tightly packed cell population with large
nuclei and clearly visible nucleoli (Fig-
ure 1A). On average, 8 3 104 infected
CD133+ cells gave rise to five hES-like
colonies that we named CBiPS. We suc-
cessfully repeated the experiment with
six independent CB units testing all three
conditions (OSKM, OSK, and OS) and
generating 27 CBiPS cell lines, of which
20 lines have been expanded and charac-
terized for endogenous expression of plu-
ripotency markers and pluripotent differ-
entiation ability in vitro. Furthermore, six
independent CBiPS lines (two lines from
each of the three reprogramming condi-
tions: CBiPS 4F-3, CBiPS 4F-5, CBiPS
3F-10, CBiPS 3F-12, CBiPS 2F-1, and
CBiPS 2F-4) have been fully character-
ized. In parallel, as control, we infected
fibroblasts and keratinocytes from a
variety of independent donors with OSK
and OS as previously described (Aasen
et al., 2008). Overall, the reprogramming
efficiency, as judged by the number of
iPSC-like colonies per 104 cells, of CB-
derived cells using OSK was between that
of keratinocytes and fibroblasts (0.45 ±
0.27, n = 5; 1.38 ± 0.51, n = 12; and 0.15 ±
0.14, n = 6, for CB-derived cells, kerati-
nocytes and fibroblasts, respectively).
Importantly, however, unlike the case ofl 5, October 2, 2009 ª2009 Elsevier Inc. 353
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(A) Timeline of cord blood stem cells reprogramming. Three days postinfection, CB CD133+ cells are trans-
ferred on feeders. Small adherent colonies are observed around day 9. Typical hES-like colonies are
clearly visible after 12 days.
(B) Genomic DNA PCR confirming the insertion of 4, 3, and only 2 transgenes.
(C) Representative phase contrast images and Alkaline Phosphatase (AP) staining of CBiPS2F-1, 3F-10,
and 4F-3 cell lines.
(D) Representative Telomerase activity in CBiPS2F, 3F and 4F cell lines. HI, Heat Inactivation; HFF, Human
Foreskin Fibroblast; C, lysis buffer as negative control; +C, positive control; QC, Quantitative Control.
(E) Immunofluorescence analysis of CBiPS2F-1 cell line for pluripotency markers. The colonies express
the embryonic markers SSEA-4, SSEA-3, TRA-1-60, TRA-1-81, and the transcription factors OCT4,
SOX2 and NANOG. Underlying fibroblasts provide a negative control. Scale bars, 250 mm.CB-derived cells, we never succeeded at
generating iPSC-like colonies from kerati-
nocytes or fibroblasts using OS, despite
numerous attempts (12 and 6, respec-
tively) performed in parallel.
In addition, since banked CB units are
stored in a cryopreserved status, in two
independent experiments, we have ge-354 Cell Stem Cell 5, October 2, 2009 ª2009nerated five CBiPS Frozen (CBiPSFr) cell
lines from thawed CB units that had
been stored frozen for more than 5 years.
The CBiPSFr cell lines were characterized
for expression of pluripotency-associated
transcription factors and surface markers,
and pluripotent differentiation ability
in vitro. These data showed that the stan-Elsevier Inc.dard cryopreservation protocol does not
affect the reprogramming ability of these
cells.
The presence of each retroviral trans-
gene was confirmed by PCR genotyping,
demonstrating the insertion of the ex-
pected 4, 3, or 2 transcription factors in
CBiPS 4F, CBiPS 3F, CBiPS 2F, respec-
tively (Figure 1B).
All the CBiPS lines tested showed
strong alkaline phosphatase (Figure 1C)
and had reactivated the enzyme telome-
rase (Figure 1D) activity. Immunofluores-
cence of 6 CBiPS cell lines revealed
expression of pluripotency markers such
as OCT4, SOX2, TRA-1-81, TRA-1-60,
SSEA3, SSEA4, and NANOG (Figure 1E
and Figures S3A and S3B). With CBiPS
cells lines derived from frozen CB units,
we obtained similar results (Figure S3C).
In addition, flow cytometry analysis re-
vealed that CBiPS cells were negative
for the hematopoietic stem cell markers
CD45 and CD34, but still positive for
CD133, a common marker of hematopoi-
etic and hESCs (Figure S4).
Quantitative RT- PCR showed that all
CBiPS lines tested expressed a set of plu-
ripotency genes, including OCT4, SOX2,
NANOG, CRIPTO, and REX1, uncovering
a gene-expression profile comparable to
other iPSC (Aasen et al., 2008) and ES
[2] lines (Raya et al., 2008) (Figure 2A).
Accordingly, the genome-wide transcrip-
tional profile of CBiPS and hES lines was
similar, as shown by microarray analysis
(Figures S5A and S5B). Quantitative RT-
PCR also revealed that the expression of
the retroviral transgenes was reduced to
low or undetectable levels and that they
correctly upregulated the endogeneous
expression of OCT4, SOX2, KLF4, and
c-MYC (Figure 2B).
Silencing of the retroviral transgenes
was further confirmed in the CBiPS2F-1
line by immunofluorescence staining using
antibodiesspecific for FLAG-tagged trans-
genic factors (Figure S6). Consistent with
these observations, bisulfite sequencing
revealed an extensive demethylation of
CpG dinucleotides of the OCT4 promoter,
reflecting the transcriptional reactivation
of this key pluripotency gene and the
epigenetic reprogramming of CBiPS cells
(Figure S7).
We confirmed the clonal origin of
CBiPS2F by subcloning this line and
finger-printing the resulting subclones by
Southern blot using probes recognizing
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(A) Quantitative RT-PCR analysis for pluripotency markers OCT4, SOX2, NANOG, REX1, CRIPTO, KLF4
and c-MYC. ES[2] and Keratinocyte-iPS (KiPS) cell lines were analyzed together with the different CBiPS
cell lines derived from fresh and frozen samples. Error bars indicate the SD generated from triplicates.
(B) Quantitative RT-PCR showing the repression of the OCT4, SOX2, KLF4, and c-MYC transgenes in the
CBiPS cell lines.
(C) In vitro differentiation of CBiPS 2F-1 into the three primary germ cell layers (Ectoderm-Tuj1 [green],
Endoderm-AFP [green] and FOXA2 [red], and Mesoderm-ASA [red] and GATA4 [green]).
(D) Immunofluorescence analysis of teratoma sections 60 days after intratesticular injection of CBiPS2F-1
showing Tuj1 (green)/GFAP (red)-positive ectoderm, AFP (green)/FoxA2 (red)-positive endoderm, and
ASM (green)/ASA (red)-positive mesoderm. Scale bar, 75–250 mm.
(E and F) Specific in vitro differentiation of CBiPS2F-1 (E) and CBiPS3F-12 (F) into dopaminergic neurons
(Tuj1 [green]/TH tyrosine hydroxilase [red]), which are immunophenotypically mature.
(G) Chromatin immuno-precipitation assays comparing the levels of histone H3 methylation at K4
(H3K4me2), K27 (H3K27me3), and K9 (H3K9me3) in the promoters of OCT4, NANOG, HOXB4, and
HOXB5 in human fibroblasts and CD133+ cells.OCT4, SOX2, KLF4, and c-MYC. As ex-
pected, the KLF4 and c-MYC probes
only recognized the endogenous genomic
sequences, whereas OCT4 and SOX2
probes revealed in the original clone
and two randomly picked subclones
(CBiPS2F-1a and CBiPS2F-1b) identical
additional bands: one for SOX2 and one
for OCT4 (Figure S8).Cytogenetic analysis showed that the
CBiPS cell lines maintained a normal
46XY or 46 XX karyotype after more than
ten passages and could be maintained
in culture for, at least, 20 passages. In
addition, the male chromosomal content
in the CBiPS4F and 2F cell lines excludes
the possibility that the reprogrammed
cells arise from a small fraction of contam-Cell Stem Cellinating mother cells known to be present
in the initial cord blood sample (Figures
S9A, S9B, and S9C).
Next, we evaluated the differentiation
potential of CBiPS lines. CBiPS cells
were able to form embryoid bodies (EBs)
with high efficiency (Figure S10A), which
could be differentiated into derivatives of
the three embryonic germ layers, in-
cluding Tuj1-positive ectoderm, a-feto-
protein (AFP), and FoxA2-positive endo-
derm, a-sarcomeric actin (ASA), and
GATA4-positive mesoderm (Figure 2C
and Figures S10B, S10C, and S10D).
Upon injection into immunocompromised
SCID beige mice, CBiPS cells generated
complex intratesticular teratomas, com-
prising structures and tissues derived
from the three embryonic germ layers,
as evidenced by the expression of Tuj1
and GFAP for ectoderm, AFP and FoxA2
for endoderm, and asmooth muscle
actin (ASM) and ASA for mesoderm (Fig-
ure 2D and Figures S10E and S10F).
Following specific in vitro differentiation
protocols, CBiPS cells gave rise also to
specialized mesoderm-derived cell types,
such as rhythmically beating cardiomyo-
cytes (Movie S1) and ectodermal cells,
such as dopaminergic neurons (Figures
2E and 2F). Our results confirm that
CBiPS cells are transcriptionally reprog-
rammed to a state similar to hiPSCs and
hESCs, are karyotypically stable, and
show a differentiation potential consistent
with pluripotency.
Since CB cells can be reprogrammed
with just two factors and are thus more
amenable to reprogramming than fibro-
blasts (Takahashi et al., 2007) or keratino-
cytes (Aasen et al., 2008), we tested
whether their global transcriptional profile
was closer to that of pluripotent stem
cells. We performed a global comparison
of the transcriptomes of CD133+ cells,
fibroblasts, keratinocytes, hESC, KiPS,
and CBiPS cells. Interestingly, the overall
transcriptional profile of CD133+ cells
was not closer to that of pluripotent
stem cells than those of fibroblasts or
keratinocytes (Figure S11A). Although
we cannot formally exclude the possibility
that a rare cell subpopulation with a tran-
scriptome similar to ESCs exists within
CD133+ cells, several lines of evidence
indicate that the increased reprogram-
ming susceptibility of CD133+ cells is a
characteristic of the majority of cells,
rather than of a rare cell population. First,5, October 2, 2009 ª2009 Elsevier Inc. 355
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tency-associated genes (Kucia et al.,
2007; Nikolova et al., 2007; Zhao et al.,
2006) such as OCT4, NANOG, SOX2,
REX1, CRIPTO, SALL2, DPPA4, ZNF589,
and DNMT3A/B (Figures S11B and
S11C), albeit at much lower levels than
ESCs (data not shown). Second, we could
not detect a subpopulation of CB cells ex-
pressing high levels of OCT4 or NANOG
by flow cytometry, but rather a normal
distribution of cells expressing low levels
of either factor (data not shown). Finally,
the overall levels of histone repressive
marks (methylation at H3K27 and H3K9)
at the OCT4 and NANOG promoters
were much lower in CB-derived stem cells
than in fibroblasts (Figure 2G). These
results indicate that the increased reprog-
ramming susceptibility of CB cells may be
the result of transcriptional differences in
a small subset of genes and a more
permissive chromatin organization. On
the other hand, the combination of high
levels of KLF4 and c-MYC in CD133+ cells
compared to fibroblasts and keratino-
cytes (Figure S11D) further underlies our
previous hypothesis that endogenous
expression of these factors may allow
for enhanced reprogramming of those
cells (Aasen et al., 2008). In support of
this notion, neuronal stem cells, which
express endogenously high levels of
SOX2, can be reprogrammed to pluripo-
tency with only OCT4 (Kim et al., 2009b,
2009c).
It has recently been shown that mobi-
lized peripheral blood (mPB) cells can be
reprogrammed to pluripotency (Loh et al.,
2009). However, compared to newborn
CB stem cells, adult mPB cells will have
the potential disadvantages that they
may have accumulated genomic alter-
ations as a result of aging or disease and
that the pharmacological treatment used
to mobilize the adult hematopoietic stem
cell compartment represents a health
risk for the donor (Anderlini, 2009). In
turn, CB-derived cells are readily available
(not requiring mobilization or biopsy and
establishment of primary cultures), young
cells (minimizing the risk of having accu-
mulated genetic mutations), and already
banked along with immunological infor-
mation. These characteristics offer evi-
dent logistic advantages over the use of
adult somatic cell types or adult stem cells
for the purpose of creating iPSC banks
(Rocha et al., 2004). To date, more than356 Cell Stem Cell 5, October 2, 2009 ª2009400,000 CB units are available worldwide
in a comprehensive network of CB banks,
facilitating a rapid and effective search for
compatible donors for CBiPS generation
(Gluckman and Rocha, 2009). Even
though the generation of patient-specific
iPS lines has been pursued in the context
of devising autologous cell-therapy strat-
egies (Raya et al., 2009), this approach
may be unfeasible in many instances.
Specifically, treatment of acute condi-
tions or situations in which the patient’s
somatic cells are altered as a conse-
quence of the disease or aging would
benefit from off-the-shelf allogeneic
approaches. Large-scale production and
banking of CBiPS lines representing a
wide panel of HLA haplotypes, organized
in a publicly available network could
therefore represent an alternative for
future clinical applications. Moreover,
selection of donors homozygous for
common HLA haplotypes could be easily
accomplished using banked CB units
and would significantly reduce the
number of CBiPS lines needed to provide
a perfect HLA match for a large per-
centage of the population (Taylor et al.,
2005). Together with the recent develop-
ments on reprogramming strategies using
nonintegrative or excisable approaches
(Kaji et al., 2009; Vandendriessche et al.,
2009; Woltjen et al., 2009; Yu et al.,
2009) or direct protein transduction (Kim
et al., 2009a), the studies presented here
should facilitate the clinical translation of
iPSC-based therapies.
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